Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Kate Haviland currently holds 26,978 shares of Fulcrum Therapeutics, Inc. (FULC), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Kate Haviland has been a net seller of FULC stock. They have purchased $48.4K and sold $11.6M worth of shares.
Kate Haviland's most recent insider trade was on Apr 29, 2026, when they sold 26,978 shares at $0.00 per share.
Kate Haviland serves as Executive at Fulcrum Therapeutics, Inc. (FULC). They have executed 104 insider transactions totaling $11.6M over their tenure at the company.
Kate Haviland holds the position of Executive at Fulcrum Therapeutics, Inc., where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 10 years and currently hold a stake valued at $0.
Kate Haviland has shown a selling trading pattern, with $48.4K in total purchases and $11.6M in total sales across all transactions. Their most recent activity indicates a tendency to reduce their position.
The largest transaction by Kate Haviland was on Mar 7, 2024, when they sold $1.1M worth of BPMC shares. This transaction involved 12,464 shares at $90.69 per share.
Kate Haviland currently owns 26,978 shares of Fulcrum Therapeutics, Inc. (FULC), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Kate Haviland's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Kate Haviland has 104 Form 4 filings on record as an insider at Fulcrum Therapeutics, Inc..
Set alerts for Kate Haviland and 40,000+ other insiders.